CHARACTERISTICS OF THE LIPID PROFILE, RENAL FUNCTION, AND INFLAMMATORY MARKERS IN PATIENTS WITH CARDIORENOMETABOLIC SYNDROME ACCORDING TO THE PRESENCE OF DIABETES MELLITUS
Abstract
A comparative analysis of clinical and laboratory parameters was performed in 140 patients diagnosed with CRMS at the Republican Specialized Scientific and Practical Medical Center of Cardiology in 2025. According to the presence of DM, patients were divided into two groups: 58 patients (41.4%) with DM and 82 patients (58.6%) without DM. Lipid profile parameters included triglycerides (TG), HDL-C, LDL-C, VLDL-C, and lipoprotein(a) [Lp(a)]. Renal function was assessed by serum creatinine, urea, and estimated glomerular filtration rate (eGFR), while systemic inflammation was evaluated by C-reactive protein (CRP). CRMS was defined according to the 2023 American Heart Association (AHA) classification. Patients with chronic kidney disease stages 3B–5 were excluded. Biochemical analyses were performed using the RANDOX Daytona automated analyzer (UK). Quantitative variables were expressed as mean ± standard deviation (M±SD), and differences between two independent groups were assessed using Welch’s t-test. A p<0.05 was considered statistically significant. Patients with CRMS and concomitant DM demonstrated higher levels of several atherogenic lipid parameters compared with patients without DM. TG levels were 2.38±1.24 and 1.90±1.18 mmol/L, respectively (p=0.023). VLDL-C levels were 1.06±0.57 mmol/L (41.18±21.90 mg/dL) in the DM group and 0.84±0.48 mmol/L (32.66±18.53 mg/dL) in the non-DM group (p=0.017).
Publication Details
This article is licensed under a Creative Commons Attribution 4.0 International License.